Therefore, our data provide further support for Lp(a) as a novel risk marker of residual risk as well as reaffirming its potential as a treatment target in coronary atherosclerosis, particularly in the population investigated here: patients with high Lp(a) already established on preventative therapies. The gene discussed is LPA; the disease is coronary atherosclerosis.